BTIG analyst Mark Massaro maintained a Hold rating on CareDx (CDNA – Research Report) on January 5. The company’s shares closed last Friday at $11.30.
According to TipRanks, Massaro is an analyst with an average return of -16.0% and a 30.80% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Cerus, and Exact Sciences.
CareDx has an analyst consensus of Hold, with a price target consensus of $10.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $18.04 and a one-year low of $4.80. Currently, CareDx has an average volume of 1.19M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx (CDNA) Company Description:
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Read More on CDNA:
